These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 8066842)

  • 21. [Prevention in bacterial meningitis].
    Spanjaard L; Bol P
    Ned Tijdschr Geneeskd; 1990 Mar; 134(12):575-7. PubMed ID: 2320157
    [No Abstract]   [Full Text] [Related]  

  • 22. Phase II meningococcal B vesicle vaccine trial in New Zealand infants.
    Jackson C; Lennon DR; Sotutu VT; Yan J; Stewart JM; Reid S; Crengle S; Oster P; Ypma E; Aaberge I; Mulholland K; Martin DR
    Arch Dis Child; 2009 Oct; 94(10):745-51. PubMed ID: 18838420
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prevention of bacterial meningitis: an overview of Cochrane systematic reviews.
    Prasad K; Karlupia N
    Respir Med; 2007 Oct; 101(10):2037-43. PubMed ID: 17706408
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Meningococcal vaccine in travelers.
    Wilder-Smith A
    Curr Opin Infect Dis; 2007 Oct; 20(5):454-60. PubMed ID: 17762777
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The hyperferremic mouse model for the evaluation of the effectiveness of VA-MENGOC-BC against Neisseria meningitidis B clinical isolates.
    Sifontes S; Infante JF; Pérez P; Caro E; Sierra G; Campa C
    Arch Med Res; 1997; 28(1):41-5. PubMed ID: 9078586
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Vaccine news: new meningitis vaccine approved for children...and should we be giving all schoolchildren flu vaccine?
    Child Health Alert; 2005 Mar; 23():1-3. PubMed ID: 15789475
    [No Abstract]   [Full Text] [Related]  

  • 27. Antibody responses to meningococcal (groups A, C, Y and W135) polysaccharide diphtheria toxoid conjugate vaccine in children who previously received meningococcal C conjugate vaccine.
    El Bashir H; Heath PT; Papa T; Ruggeberg JU; Johnson N; Sinha R; Balfour G; Booy R
    Vaccine; 2006 Mar; 24(14):2544-9. PubMed ID: 16417952
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Vaccines against bacterial meningitis.
    Segal S; Pollard AJ
    Br Med Bull; 2004; 72():65-81. PubMed ID: 15802609
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Meningococcal vaccine].
    de Moraes JC
    Rev Saude Publica; 1997 Apr; 31(2):214-6. PubMed ID: 9497571
    [No Abstract]   [Full Text] [Related]  

  • 30. [Vaccination against A-C meningococcal meningitis: ethics and management].
    Fernández Fraga C
    Aten Primaria; 1998 Apr; 21(7):502, 504. PubMed ID: 9656594
    [No Abstract]   [Full Text] [Related]  

  • 31. Mucosal immunity and optimizing protection with meningococcal serogroup B vaccines.
    Heyderman RS; Davenport V; Williams NA
    Trends Microbiol; 2006 Mar; 14(3):120-4. PubMed ID: 16469496
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Current status--meningococcal vaccine.
    Merchant R; Divekar R
    Indian J Pediatr; 1988; 55(2):256-60. PubMed ID: 3042624
    [No Abstract]   [Full Text] [Related]  

  • 33. The efficacy of meningococcal polysaccharide vaccine in preventing group A meningococcal disease in The Gambia, West Africa.
    Greenwood BM; Smith AW; Hassan-King M; Bijlmer HA; Shenton FC; Hughes AS; Nunn PP; Jack AD; Gowers PR
    Trans R Soc Trop Med Hyg; 1986; 80(6):1006-7. PubMed ID: 3603632
    [No Abstract]   [Full Text] [Related]  

  • 34. Meningococcal vaccine and herd immunity.
    Ozsoylu S
    Lancet; 2000 Mar; 355(9208):1015; author reply 1016. PubMed ID: 10768459
    [No Abstract]   [Full Text] [Related]  

  • 35. Meningococcal C conjugate vaccine: the experience in England and Wales.
    Campbell H; Borrow R; Salisbury D; Miller E
    Vaccine; 2009 Jun; 27 Suppl 2():B20-9. PubMed ID: 19477053
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Chemoprophylaxis in meningitis].
    Otero MC; Calvo MA; Pérez-Tamarit D; Asensi F
    Rev Esp Quimioter; 1998 Jun; 11(2):118-27. PubMed ID: 9795296
    [No Abstract]   [Full Text] [Related]  

  • 37. [Meningococcal disease in the City of Havana before and after vaccination].
    Rodríguez AP; Serpa IM; García M
    Rev Cubana Med Trop; 2002; 54(2):106-12. PubMed ID: 15849936
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The changing epidemiology of meningococcal meningitis after introduction of bivalent A/C polysaccharide vaccine into school-based vaccination programs in Egypt.
    Nakhla I; Frenck RW; Teleb NA; El Oun S; Sultan Y; Mansour H; Mahoney F
    Vaccine; 2005 May; 23(25):3288-93. PubMed ID: 15837234
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Meningitis Vaccine Project.
    LaForce FM; Konde K; Viviani S; Préziosi MP
    Vaccine; 2007 Sep; 25 Suppl 1():A97-100. PubMed ID: 17521780
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Fast tracking the vaccine licensure process to control an epidemic of serogroup B meningococcal disease in New Zealand.
    Lennon D; Jackson C; Wong S; Horsfall M; Stewart J; Reid S
    Clin Infect Dis; 2009 Aug; 49(4):597-605. PubMed ID: 19622040
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.